Cofactor Genomics Inc. opened the non-small-cell lung cancer portion of its study of the Oncoprism test, which predicts response to immunotherapy. The Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies (PREDAPT) trial will study the test’s predictive ability in 11 cancers in total.
Guardant Health Inc. reported positive results from the ECLIPSE trial demonstrating 83% sensitivity of its DNA blood test in detecting colorectal cancer (CRC) in average-risk adults. Specificity was 90% in people without advanced neoplasia, as well as in those who had a negative colonoscopy result.
Novartis AG has identified triazolo-pyrimidine analogues acting as Werner syndrome ATP-dependent helicase (WRN) inhibitors reported to be useful for the treatment of cancer.
Innocure Therapeutics Inc. has divulged piperidinediones as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to bromodomain-containing protein 4 (BRD4)- and/or tyrosine-protein phosphatase non-receptor type 11 (PTPN11)-targeting moiety via linker reported to be useful for the treatment of cancer.
Halda Therapeutics Opco Inc. has patented proteolysis-targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently bonded to a protein-targeting moiety via linker reported to be useful for the treatment of cancer and hepatitis.
Researchers from Fudan University presented data from a study that aimed to assess the significance of a newly found long noncoding RNA (lncRNA), Ewing sarcoma-associated transcript 1 (EWSAT1), in hepatocellular carcinoma (HCC) metastasis.
Several STING agonists have demonstrated antitumor efficacy in preclinical studies and are currently under clinical development. However, systemic administration of STING agonists may have adverse effects, while intratumoral injection is limited by tumor accessibility. Therefore, systemic delivery of STING agonists specifically targeted to tumors emerges as a potential strategy to overcome these limitations.
TSC22 domain family member 3 (TSC22D3) is a glucocorticoid-induced gene that plays a key regulatory role in immunosuppression and cell proliferation. Its prognostic usefulness in acute myeloid leukemia (AML) has not been deeply investigated yet.
Repeat expansions of two or more base pairs cause dozens of neurological disorders – Huntington’s disease, which is caused by an expansion of the triplet CAG in the coding sequence for huntingtin, is perhaps the most famous one. Now, investigators at Stanford University have shown that cancer genomes, too, frequently feature repeat expansions.
RSS
